Emerging drugs for the treatment of soft tissue sarcomas (Q36758596)

16 August 2017

1 reference

title

Emerging drugs for the treatment of soft tissue sarcomas (English)

1 reference

16 August 2017

7

Jean-Yves Blay

0 references

Isabelle Ray-Coquard

series ordinal

6

object named as

Isabelle Ray-Coquard

0 references

Laurent Alberti

series ordinal

4

object named as

Laurent Alberti

1 reference

Philippe Alexandre Cassier

16 August 2017

series ordinal

1

object named as

Philippe A Cassier

1 reference

16 August 2017

3

Jérôme Fayette

1 reference

16 August 2017

2

Armelle Dufresne

1 reference

16 August 2017

Dominique Ranchere

5

1 reference

16 August 2017

language of work or name

English

0 references

publication date

1 March 2007

1 reference

Expert Opinion on Emerging Drugs

16 August 2017

published in

1 reference

16 August 2017

volume

12

1 reference

16 August 2017

issue

1

1 reference

16 August 2017

page(s)

139-153

1 reference

Mechanisms of sarcoma development

16 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1517/14728214.12.1.139

PDGFRA mutations in gastrointestinal stromal tumors: frequency, spectrum and in vitro sensitivity to imatinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14728214.12.1.139

Clinical management of gastrointestinal stromal tumors: before and after STI-571.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14728214.12.1.139

Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14728214.12.1.139

Combined surgical and molecular therapy: the gastrointestinal stromal tumor model

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14728214.12.1.139

Gastrointestinal stromal tumors: the incidence, prevalence, clinical course, and prognostication in the preimatinib mesylate era--a population-based study in western Sweden

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14728214.12.1.139

Biology of gastrointestinal stromal tumors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14728214.12.1.139

Gain-of-Function Mutations of c- kit in Human Gastrointestinal Stromal Tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14728214.12.1.139

PDGFRA activating mutations in gastrointestinal stromal tumors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14728214.12.1.139

Gastrointestinal stromal tumors: pathology and prognosis at different sites

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14728214.12.1.139

Surgical management of advanced gastrointestinal stromal tumors after treatment with targeted systemic therapy using kinase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14728214.12.1.139

Surgical treatment of patients with initially inoperable and/or metastatic gastrointestinal stromal tumors (GIST) during therapy with imatinib mesylate

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14728214.12.1.139

Consensus meeting for the management of gastrointestinal stromal tumors. Report of the GIST Consensus Conference of 20-21 March 2004, under the auspices of ESMO.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14728214.12.1.139

Outcome of patients with advanced gastro-intestinal stromal tumours crossing over to a daily imatinib dose of 800 mg after progression on 400 mg.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14728214.12.1.139

Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14728214.12.1.139

Nilotinib in imatinib-resistant CML and Philadelphia chromosome-positive ALL

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14728214.12.1.139

Prognostic factors for the outcome of chemotherapy in advanced soft tissue sarcoma: an analysis of 2,185 patients treated with anthracycline-containing first-line regimens--a European Organization for Research and Treatment of Cancer Soft Tissue and

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14728214.12.1.139

Improving the management of soft tissue sarcoma. Diagnosis and treatment should be given in specialist centres

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14728214.12.1.139

Review: tubulin function, action of antitubulin drugs, and new drug development

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14728214.12.1.139

Epothilones: mechanism of action and biologic activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14728214.12.1.139

Gemcitabine in advanced adult soft-tissue sarcomas. A phase II study of the EORTC Soft Tissue and Bone Sarcoma Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14728214.12.1.139

Phase II trial of paclitaxel in patients with soft-tissue sarcoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14728214.12.1.139

Gemcitabine and docetaxel in patients with unresectable leiomyosarcoma: results of a phase II trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14728214.12.1.139

Docetaxel and gemcitabine combination in 133 advanced soft-tissue sarcomas: a retrospective analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14728214.12.1.139

Phase II study of ecteinascidin-743 in advanced pretreated soft tissue sarcoma patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14728214.12.1.139

Phase II study of ET-743 in advanced soft tissue sarcomas: a European Organisation for the Research and Treatment of Cancer (EORTC) soft tissue and bone sarcoma group trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14728214.12.1.139

Phase II and pharmacokinetic study of ecteinascidin 743 in patients with progressive sarcomas of soft tissues refractory to chemotherapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14728214.12.1.139

Ecteinascidin-743 (ET-743) for chemotherapy-naive patients with advanced soft tissue sarcomas: multicenter phase II and pharmacokinetic study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14728214.12.1.139

A phase II and pharmacokinetic study of ecteinascidin 743 in patients with gastrointestinal stromal tumors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14728214.12.1.139

A phase I dose-escalation and pharmacokinetic study of brostallicin (PNU-166196A), a novel DNA minor groove binder, in adult patients with advanced solid tumors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14728214.12.1.139

Brostallicin, an agent with potential activity in metastatic soft tissue sarcoma: a phase II study from the European Organisation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14728214.12.1.139

Effect of the tyrosine kinase inhibitor STI571 in a patient with a metastatic gastrointestinal stromal tumor

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14728214.12.1.139

Safety and efficacy of imatinib (STI571) in metastatic gastrointestinal stromal tumours: a phase I study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14728214.12.1.139

Progression-free survival in gastrointestinal stromal tumours with high-dose imatinib: randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14728214.12.1.139

Dasatinib (BMS-354825), a dual SRC/ABL kinase inhibitor, inhibits the kinase activity of wild-type, juxtamembrane, and activation loop mutant KIT isoforms associated with human malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14728214.12.1.139

AMG 706, an oral, multikinase inhibitor that selectively targets vascular endothelial growth factor, platelet-derived growth factor, and kit receptors, potently inhibits angiogenesis and induces regression in tumor xenografts

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14728214.12.1.139

Mechanisms of resistance to imatinib mesylate in gastrointestinal stromal tumors and activity of the PKC412 inhibitor against imatinib-resistant mutants

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14728214.12.1.139

Effects of PKC412, nilotinib, and imatinib against GIST-associated PDGFRA mutants with differential imatinib sensitivity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14728214.12.1.139

Targeting mammalian target of rapamycin synergistically enhances chemotherapy-induced cytotoxicity in breast cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14728214.12.1.139

Thalidomid: current role in the treatment of non-plasma cell malignancies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14728214.12.1.139

Phase II study of doxorubicin and bevacizumab for patients with metastatic soft-tissue sarcomas.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14728214.12.1.139

Phase III study of matrix metalloproteinase inhibitor prinomastat in non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14728214.12.1.139

Randomized phase III study of matrix metalloproteinase inhibitor BMS-275291 in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: National Cancer Institute of Canada-Clinical Trials Group Study BR.18.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14728214.12.1.139

Comparison of gemcitabine versus the matrix metalloproteinase inhibitor BAY 12-9566 in patients with advanced or metastatic adenocarcinoma of the pancreas: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14728214.12.1.139

A phase I and pharmacokinetic study of Col-3 (Metastat), an oral tetracycline derivative with potent matrix metalloproteinase and antitumor properties

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14728214.12.1.139

Expression of epidermal growth factor receptor, ERBB2 and KIT in adult soft tissue sarcomas: a clinicopathologic study of 281 cases

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14728214.12.1.139

Phase I study of the safety, tolerability, pharmacokinetics, and pharmacodynamics of PTK787/ZK 222584 administered twice daily in patients with advanced cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14728214.12.1.139

Prognostic and therapeutic relevance of HER2 expression in osteosarcoma and Ewing's sarcoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14728214.12.1.139

Molecular and immunohistochemical analysis of HER2/neu oncogene in synovial sarcoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14728214.12.1.139

Tissue microarray immunohistochemical expression of estrogen, progesterone, and androgen receptors in uterine leiomyomata and leiomyosarcoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14728214.12.1.139

Endocrine therapy for desmoid tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14728214.12.1.139

Estrogen receptor-beta expression in extraabdominal fibromatoses: an analysis of 40 cases

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14728214.12.1.139

Phase I and pharmacologic study of 17-(allylamino)-17-demethoxygeldanamycin in adult patients with solid tumors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14728214.12.1.139

Normal and oncogenic forms of the receptor tyrosine kinase kit.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14728214.12.1.139

PDGF receptors as cancer drug targets

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14728214.12.1.139

Switching on kinases: oncogenic activation of BRAF and the PDGFR family

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14728214.12.1.139

Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14728214.12.1.139

KIT mutations and dose selection for imatinib in patients with advanced gastrointestinal stromal tumours

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14728214.12.1.139

In vivo activation of the p53 pathway by small-molecule antagonists of MDM2

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14728214.12.1.139

mTOR and cancer: insights into a complex relationship

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14728214.12.1.139

A phase I and pharmacokinetic study of temsirolimus (CCI-779) administered intravenously daily for 5 days every 2 weeks to patients with advanced cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14728214.12.1.139

Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14728214.12.1.139

A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14728214.12.1.139

Inducer-stimulated Fas targets activated endothelium for destruction by anti-angiogenic thrombospondin-1 and pigment epithelium-derived factor

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14728214.12.1.139

Concentration of vascular endothelial growth factor in the tumour tissue as a prognostic factor of soft tissue sarcomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14728214.12.1.139

Vascular endothelial growth factor overexpression by soft tissue sarcoma cells: implications for tumor growth, metastasis, and chemoresistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14728214.12.1.139

A small interfering RNA targeting vascular endothelial growth factor inhibits Ewing's sarcoma growth in a xenograft mouse model

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14728214.12.1.139

Tumour microenvironment - opinion: validating matrix metalloproteinases as drug targets and anti-targets for cancer therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14728214.12.1.139

HSP90 and the chaperoning of cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14728214.12.1.139

Hsp90 inhibitor 17-allylamino-17-demethoxygeldanamycin prevents synovial sarcoma proliferation via apoptosis in in vitro models

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14728214.12.1.139

Conformity to clinical practice guidelines, multidisciplinary management and outcome of treatment for soft tissue sarcomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14728214.12.1.139

Circulating angiogenic factor levels correlate with extent of disease and risk of recurrence in patients with soft tissue sarcoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14728214.12.1.139

10.1517/14728214.12.1.139

21 January 2018

Identifiers

DOI

1 reference

16 August 2017

1 reference